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Abstract: Recently, the US Food and Drug Administration issued an alert about an increased 
risk for suicidality during treatment with antiepileptic drugs (AEDs) for different indications, 
including epilepsy. We discuss the issue of suicide in epilepsy with special attention to AEDs 
and the assessment of suicide in people with epilepsy. It has been suggested that early medical 
treatment with AEDs might potentially reduce suicide risk of people with epilepsy, but it is of 
great importance that the choice of drug is tailored to the mental state of the patient. The issue 
of suicidality in epilepsy is likely to represent an example of how the underdiagnosis of 
psychiatric symptoms, the lack of input from professionals (eg, psychologists, social workers, 
and psychiatrists), and the delay in an optimized AED therapy may worsen the prognosis of the 
condition with the occurrence of severe complications such as suicide.
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The background: suicide in people with epilepsy
It was first suggested many years ago that, despite popular opinion, suicide occurred 
“rather frequently” in people with epilepsy.1 Since that time increasing evidence has 
accumulated,2 and it seems that the overall risk of committing suicide in people with 
epilepsy is about 3 times that of the general population.3
The relationship between epilepsy and suicide has been investigated in a few studies 
using a case-control design, mostly in Scandinavia. One of these, using national regis-
tries, included every person ascertained as having committed suicide in Denmark during 
a 17-year period and also up to 20 age-matched and sex-matched controls, still alive, 
for each person who committed suicide.4 Rate ratios, corrected for marital status, labor 
market status, income, place of residence, and sickness absence were estimated. Of 
more than 20,000 people who committed suicide, 492 (2.3%) had a history of epilepsy 
compared with 3,140 (0.7%) controls (rate ratio, 3.17). Those with epilepsy were 4 times 
as likely to have a history of psychiatric disease (as listed in the Danish Psychiatric 
Central Register) as those without epilepsy. In people with no history of psychiatric 
disease, the adjusted rate ratio of suicide in people with epilepsy was 1.99 (95% con-
fidence interval [CI], 1.71–2.32) compared with those without epilepsy. The rate ratio 
of suicide in those with both epilepsy and psychiatric disease was 13.7 compared with 
those without epilepsy or psychiatric disease. Whether or not psychiatric disease was 
present in those with epilepsy, the risk of suicide was greatest in the early stages of 
the condition, usually in the first 6 months after epilepsy diagnosis.
Another case-control study was nested within a cohort study of adults admitted at 
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of epilepsy recorded at discharge.5 Subsequently, 26 patients 
committed suicide, and these were matched with 171 patients 
from the same population who were alive at the end of the 
study period. A 9-fold increase in risk of suicide associated 
with psychiatric illness and a similar increase associated with 
the use of antipsychotic drugs were found. The risk associated 
with antipsychotic drugs was still increased (almost 4-fold) 
after adjusting for psychiatric illness and alcohol abuse. In 
this study, which could look at epilepsy variables, early age 
of onset of epilepsy was strongly associated with suicide. 
Both seizure frequency in the previous year and number of 
AEDs taken showed weak (nonsignificant) relationships with 
suicide, but numbers of suicides were small.
All suicides that occurred in a 15-year period in a region 
of Finland were investigated.6 Of 1,877 people who com-
mitted suicide, 25 had hospital-treated epilepsy. Those with 
epilepsy were more likely to have had psychiatric disorders 
than those without epilepsy.
The cause of the increased risk of suicide associated with 
epilepsy is not entirely clear. In the past, it was linked to 
socioeconomic deprivation associated with epilepsy.7 More 
recently, other risk factors have been suggested. Previous 
suicide ideation or attempt is a risk factor for suicide,2,8 so it 
is also important to assess risk factors for suicidality.
Psychiatric disorders may occur twice as frequently in 
people with epilepsy as in the general population9 and, in 
the general population, approximately 90% of people who 
commit suicide have psychiatric disorders at the time.10 There 
is increasing evidence that the comorbidity of depression and 
epilepsy may be bidirectional, ie, that people with epilepsy 
may be more prone to developing depression and that people 
with depression may be more likely to develop epilepsy.11 
Similarly, a previous attempt to suicide is associated with 
an increased risk of seizure onset, even after adjusting for 
depression.11 One study in Nigeria compared people with 
epilepsy, population controls, and a small control group 
with major depression. A questionnaire was used to identify 
depression and suicidal ideation. More people with epilepsy 
had depression than population controls. Suicidal ideation 
levels were similar in depressed people with epilepsy and in 
population controls with depression, but suicidal ideation was 
significantly higher in the controls with major depression.12 
A questionnaire study from Italy included 103 people with 
temporal lobe epilepsy, excluding people with current 
dementia or psychosis. One quarter of people with epilepsy 
had high levels of hopelessness, suggesting they were at risk 
of suicide.13
A recent study from Brazil attempted to contact all 
people aged 13 years and older, who had been identified in 
a previous population-based study of people with epilep-
sy.14 People were asked to complete a questionnaire, and 
some also had a detailed psychiatric evaluation. Of those 
who participated (four-fifths of the original cohort), more 
than one-third reported suicidal ideation, almost one-fifth 
had made suicidal plans, and 12% had attempted suicide 
at least once. Those reporting suicidal thoughts had more 
anxiety, more depression, and were more likely to be on 
current mental health treatment. They were also more likely 
to be female, to be older, to have active epilepsy, and to have 
visited the emergency department more frequently.14 Another 
study, based largely on the same population, compared 
153 people with epilepsy with 154 neighborhood controls. 
People with epilepsy were more likely to report depression 
and anxiety, and had significantly raised odds ratios for 
suicidal thoughts, suicidal plans, and attempted suicide at 
some stage in life.15
All data presented clearly suggest that suicide is over-
represented in people with epilepsy. A recent meta-analysis 
estimated the overall SMR for suicide in people with epi-
lepsy as 3.3 (95% CI, 2.8–3.7). The SMR, however, ranges 
between 2.1 for people with newly diagnosed epilepsy in the 
community and 13.9 in those following temporal lobe resec-
tions.3 This is probably due to a number of reasons that are 
both biological and psychosocial. More data are warranted, 
and well-designed studies are needed to identify and isolate 
relevant variables.
The assessment of suicide  
risk in clinical practice
In psychiatric practice, it is generally agreed that mental 
disorders increase the risk for suicide, especially when sub-
stance abuse or depressive symptoms coexist with another 
psychiatric disorder or condition.16 A number of psychosocial 
factors are also associated with risk for suicide and suicide 
attempts.17 These include recent life events such as losses, 
especially employment, career, finance, housing, marital 
relationship, physical health, and a sense of a future, and 
chronic or long-term problems such as relationship difficul-
ties, unemployment, and problems with the legal authorities. 
Psychological states of acute distress (especially humiliation, 
despair, guilt and shame) are often present in association 
with suicidal ideation, planning, and attempts. Although not 
uniformly predictive of suicidal ideation and behavior, they 
are warning signs of psychological vulnerability and indicate Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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a need for mental health evaluation to minimize immediate 
discomfort and to evaluate suicide risk. Nevertheless, these 
risk factors are not necessarily closely related in time to the 
onset of suicidal behaviors – nor does any risk factor alone 
increase or decrease risk. Population-based research suggests 
that the risk for suicide increases with an increase in the num-
ber of risk factors present such that when more risk factors are 
present at any one time, the more likely it is that they indicate 
an increased risk for suicidal behaviors at that time.18
Are there warning signs for clinicians about suicide? There 
are 3 major pointers as follows: threatening to hurt or kill self; 
looking for ways to kill self such as seeking access to drugs, 
weapons, or other means; talking or writing about death, dying, 
or suicide.19 The remaining list of warning signs should alert the 
clinician that a mental health evaluation needs to be conducted 
in the very near future and that precautions need to be put into 
place immediately to ensure the safety, stability, and security 
of the individual: hopelessness; rage, anger, seeking revenge; 
acting recklessly or engaging in risky activities, seemingly 
without thinking; feeling trapped, like there is no way out; 
increasing alcohol or drug abuse; withdrawing from friends, 
family, or society; anxiety, agitation, being unable to sleep 
or sleeping all the time; dramatic changes in mood; feeling 
no reason for living; and having no sense of purpose in life. 
Other behaviors that may be associated with increased short-
term risk for suicide include the patient making arrangements 
to divest responsibility for dependent others (children, pets, 
elders) or making other preparations such as updating wills, 
making financial arrangements for paying bills, saying farewell 
to loved ones.17,19
It is important to emphasize at this point that a number 
of specific variables may increase or decrease the risk of 
suicide.17,19 They do not necessarily impart a causal relation-
ship but rather they serve as guidelines for the clinician to 
weigh the relative risk of an individual engaging in suicidal 
behaviors within the context of the current clinical presenta-
tion and psychosocial setting. In fact, individuals differ in 
the degree to which risk and protective factors affect their 
propensity for engaging in suicidal behaviors, and, within an 
individual, the contribution of each risk and protective factor 
to their suicidality will vary over the course of their lives. 
No one risk factor, or set of risk factors, necessarily conveys 
increased suicidal risk. Nor does one protective factor, or set 
of protective factors, insure protection against engagement in 
suicidal behaviors. Furthermore, because of their different sta-
tistical correlations with suicidal behaviors, these factors are 
not equal and one cannot “balance” one set of factors against 
another in order to derive a total score of relative suicidal 
risk. Some risk factors are unchallengeable (eg, age, gender, 
race/ethnicity), whereas others are more situation-specific (eg, 
loss of housing, exacerbation of pain in a chronic condition, 
and onset or exacerbation of psychiatric symptoms).
Ideally, with the elucidation and knowledge of an individ-
ual’s risk and protective factors as a backdrop, the sensitive 
clinician will inquire about the individual’s reasons for living 
and for dying to better evaluate current risk for suicide.
Factors that may increase a person’s risk have been 
mentioned already. Conversely, those that may decrease 
the risk for suicide are called protective factors and include 
the following: positive social support; spirituality; sense of 
responsibility to family; children in the home, pregnancy; 
life satisfaction; reality testing ability; positive coping 
skills; positive problem-solving skills; positive therapeutic 
relationship.
The US Food and Drug 
Administration meta-analysis
In 2005, the US Food and Drug Administration (FDA) 
became concerned that there may be an excess risk of sui-
cidal ideation or behavior associated with the use of AEDs. 
They requested that sponsors of AED studies submit data 
from placebo-controlled trials and then performed a meta-
analysis of suicidal behavior and ideation based on previously 
defined criteria. Results were published in 2008.20 Eleven 
AEDs, used for any indication, were involved in the 199 
placebo-controlled trials, with more than 27,000 patients 
taking AEDs and 16,000 taking placebo. Most of the trials 
were of short duration (mean 89 days; maximum 582 days) 
and one-fourth of patients were in epilepsy trials, just over 
one-fourth in trials with psychiatric indications and almost 
50% in trials for “other” indications (including agitation, 
pain, obesity, and tremor). Two newer AEDs (topiramate 
27% and pregabalin 24%) accounted for 50% of the patients 
in the trials, and older AEDs for very few (carbamazepine 
1%, valproate 5%, and phenytoin and phenobarbital were 
not included in any of the trials).
Four people committed suicide (all on AEDs and none on 
placebo). In the AED group, 0.37% of patients had suicidal behav-
ior or ideation compared with 0.24% in the placebo group; most 
events, however, were suicidal ideation. The overall odds ratio for 
suicidal behavior or ideation was 1.8 (95% CI, 1.24–2.66). The 
odds ratios were significantly increased for topiramate and lam-
otrigine and were (nonsignificantly) decreased for carbamazepine 
and valproate. The odds ratios were significantly increased for Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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suicidal behavior or ideation in trials for epilepsy indications but 
not in trials for psychiatric or other indications. It should be noted, 
however, that in most epilepsy trials, the AED was not used in 
  monotherapy, whereas in trials with psychiatric or other indica-
tions, the AED was used in monotherapy in 75%–86% of trials.
As a result of the meta-analysis, the FDA issued an alert 
about the use of AEDs, in which they state that any patients 
taking AEDs should be monitored for any suggestion of 
suicidal thoughts or behavior, or depression. They also state 
that patients and their families and caregivers should be 
warned that AEDs may increase the risk of suicidal thoughts 
or actions and that manufacturers of AEDs should include a 
warning in the drug labeling to this effect.21
Following the FDA meta-analysis, further studies have 
attempted to investigate the relationship between AEDs and 
suicide. A study from Denmark using national registers of 
prescriptions, comorbidity, psychiatric diagnoses, and cause 
of death used 2 different methodologies to investigate this 
relationship.22 In the first analysis, each individual who 
committed suicide during a 10-year period and who had also 
taken AEDs during that 10-year period was considered. The 
control for each person who committed suicide was that same 
individual during a control period of 30 days, 2 (or 3) months 
before the suicide. Thus, the number of people taking AEDs 
during the 30-day period prior to the suicide was compared 
with the number of the same people who took AEDs in a 
30-day period 2 (or 3) months earlier. Overall, AED usage 
increased the risk of suicide, as did the use of clonazepam, 
valproate, lamotrigine, or phenobarbital. The second analysis 
included only people who started taking AEDs during the 
10-year period and who had not been prescribed AEDs in 
the year prior to the 10-year period. Survival analysis of 
suicide during the first 6 months of exposure to an AED 
found hazard ratios that were increased (compared with 
carbamazepine) for clonazepam, valproate, lamotrigine, 
phenobarbital, and levetiracetam. It is pointed out that only 
a minority of the cohort was registered as having epilepsy 
and that individuals may have restarted AED treatment in 
response to worsening of underlying psychiatric or pain-
related symptoms. It is interesting that valproate appeared 
to increase the risk of suicide, which was not the case in the 
FDA meta-analysis.
Investigators in the United States used Veterans Health 
Administration data to assess suicide-related behaviors in 
people with a new prescription for monotherapy AED. For each 
person aged 66 years and older with new AED treatment, who 
had suicide-related behavior, 12 controls were found, matched 
according to a previous history of suicide-related behavior, 
the year of first AED prescription, and a diagnosis of epilepsy. 
Gabapentin was used as the reference AED, as more than 75% 
of individuals received this drug. Compared with gabapentin, 
there was a slight increase in suicide-related behaviors in those 
taking the newer AEDs (levetiracetam or lamotrigine), but the 
confidence intervals were wide. The strongest predictor for 
suicide-related behavior was found to be having an affective 
disorder diagnosed prior to the AED prescription. In this group 
with new AED prescriptions, the FDA’s finding that suicidal 
behavior was more common in those with epilepsy than in those 
using AEDs for other indications was not confirmed.23
Another US cohort study using the HealthCore Integrated 
Research Database reported an increased risk of suicidal attempts 
and completed suicide or violent death in patients taking gaba-
pentin, lamotrigine, oxcarbazepine, tiagabine and valproate 
compared with topiramate24 regardless of a specific indication. 
Only a small proportion of the cohort was taking AEDs for 
epilepsy, ranging from 0.3% to 19%, and the median follow-up 
was 60 days. In the epilepsy subanalysis (compared with car-
bamazepine), it seemed that gabapentin was associated with an 
increased suicidal risk. In common with other studies in the field, 
the lack of pretreatment data represents a major limitation.
Do AEDs increase or reduce  
the risk of suicide in epilepsy?
It has been suggested that the concern of the FDA over all 
AEDs might be excessive, particularly as the meta-analysis 
only found statistically significant effects for 2 AEDs.25,26 The 
methodology of using only spontaneously reported suicidal-
ity events has been questioned.26 It has also been suggested 
that the risk of uncontrolled seizures (due to stopping or not 
starting AEDs) might well be in excess of the risk of sui-
cidality.26,27 The rate of suicide is almost certainly increased 
in people with epilepsy,3,27 but the number of deaths due to 
suicide in people with epilepsy is much smaller than those due 
to accidents or Sudden Unexpected Death in Epilepsy which 
seem to be related to the frequency of seizures.26
A study using the UK General Practice Research 
Database investigated people with incident epilepsy 
(defined as a diagnostic code of epilepsy and at least 2 AED 
prescriptions) and up to 4 matched controls for each person 
with incident epilepsy. With more than 3,000 people with 
epilepsy and 11,000 controls, the incidence rate ratio (IRR) 
was significantly increased for suicide attempt before the 
diagnosis of epilepsy and for the first year after the diag-
nosis.28 Looking at suicide recurrence in subjects with a 
previous history of suicide attempt, however, the IRR was 
actually decreased after epilepsy diagnosis and epilepsy drug Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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treatment was started, suggesting that AEDs actually decrease 
the risk of suicide.
Data from the RANSOM study suggested that nonadherence 
to AEDs can have serious or fatal consequences for patients 
with epilepsy with a 3-fold increase in mortality risk compared 
with patients who are adherent to drug treatment.29
Emerging data from the field of psychiatry are of particular 
interest. A US pharmacoepidemiologic study using the 
PharMetrics medical claims database reported that AEDs 
do not increase the risk of suicide attempts in patients with 
bipolar disorder compared with those not treated with AEDs or 
lithium.30 Conversely, the use of AEDs reduced suicide attempt 
rates both relative to patients not receiving any psychotropic 
medication and relative to their pretreatment levels.
All these findings taken together clearly suggest that 
advantages from an appropriate treatment of seizures 
in people with epilepsy clearly overcome potential 
disadvantages, making AEDs potentially protective agents 
against suicide. In agreement with others, we suggest 
that early medical treatment with AEDs could potentially 
reduce the suicide risk of people with epilepsy because of 
the mood-stabilizing properties of some compounds,4 but 
it becomes even more important that the drug choice needs 
to be tailored to the mental state of the patient. The choice 
of a specific AED is influenced by a number of variables 
including, but not restricted to, the type of seizure or the 
epilepsy syndrome. Side-effect profile of the drug, indi-
vidual circumstances of the patient including the mental 
state, affordability, and personal preferences need to be 
taken into account.
The prognosis of epilepsy and the occurrence of severe 
complications, including suicide, may be made worse by 
missing important comorbidity and by delaying or with-
holding treatment. These issues may be compounded by the 
lack of input from professionals such as psychologists, social 
workers, and psychiatrists.
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